REG - Hikma Pharmaceutical - Director/PDMR Shareholding
RNS Number : 2787SHikma Pharmaceuticals Plc15 March 2021
Hikma Pharmaceuticals PLC - EIP B Vesting
LONDON, 15 March 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element B.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Said Darwazah
2
Reason for the notification
a)
Position/status
Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. All Shares were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 61,666
d)
Aggregated information
- Volume
- Price
- Total
61,666
£0.00
£0.00
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Siggi Olafsson
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Sigurdur Olafsson
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 35,513
Price(s): £22.057
Volume(s): 31,794
d)
Aggregated information
- Volume
- Price
- Total
67,307
£22.057
£701,280.26
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Mazen Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mazen Darwazah
2
Reason for the notification
a)
Position/status
Executive Vice Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. All Shares were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 42,572
d)
Aggregated information
- Volume
- Price
- Total
42,572
£0.00
£0.00
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Riad Mishlawi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Riad Mishlawi
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. All Shares were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 32,027
d)
Aggregated information
- Volume
- Price
- Total
32,027
£0.00
£0.00
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Majda Labadi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Majda Labadi
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. All Shares were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 17,091
d)
Aggregated information
- Volume
- Price
- Total
17,091
£0.00
£0.00
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Bassam Kanaan
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Bassam Kanaan
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. All Shares were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 27,193
d)
Aggregated information
- Volume
- Price
- Total
27,193
£0.00
£0.00
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Khalid Nabilsi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Khalid Nabilsi
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. All Shares were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 25,089
d)
Aggregated information
- Volume
- Price
- Total
25,089
£0.00
£0.00
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Brian Hoffmann
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Brian Hoffmann
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 8,435
Price(s): £22.057
Volume(s): 7,552
d)
Aggregated information
- Volume
- Price
- Total
15,987
£22.057
£166,574.46
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Susan Ringdal
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Susan Ringdal
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 7,626
Price(s): £22.057
Volume(s): 6,828
d)
Aggregated information
- Volume
- Price
- Total
14,454
£22.057
£150,605.20
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Henriette Nielsen
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Henriette Nielsen
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of conditional awards on
12 March 2021 under the EIP Element B. Shares were sold to cover tax and the remainder were retained.c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 4,627
Price(s): £22.057
Volume(s): 5,275
d)
Aggregated information
- Volume
- Price
- Total
9,902
£22.057
£116,350.68
e)
Date of the transaction
12 March 2021
f)
Place of the transaction
London Stock Exchange (XLON)
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 276015 March 2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHBBGDXSDBDGBU
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Final Results
Announcement